VESPER-2 Ildiko Lingvay First, Ildiko Lingvay, MD, MPH, MSCS, tenured professor of medicine at UT Southwestern Medical Center in Dallas, presented results from VESPER-2, a randomized, double-blind, 28-week placebo-controlled study that evaluated efficacy and safety of four weekly doses of berobenatide (0.4 mg, 0.8 mg, 1.2 mg, 1.6 mg), compared with placebo, among adults with obesity or overweight in addition to type 2 diabetes
Strategies that support microbial diversity, including probiotic supplementation (particularly Lactobacillus and Bifidobacterium strains studied in atopic conditions), prebiotic fiber intake, and avoidance of unnecessary antibiotics, create a more favorable environment for peptide interventions
Gluthione Transferases and Gamma-Glutamyl Transpeptidases
Quercetin prevented VPA-induced behavioral impairments and attenuated oxidative alterations across multiple brain regions, supporting its antioxidant and neuroprotective potential in this ASD model ( Since quercetin itself in low concentrations is poorly absorbed, can hardly cross the BBB and is quickly eliminated, the study of Moghaddam used quercetin-loaded nanophytosome (QNP) against autism-like damage in maternal separation model
